FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS


Clozapine immunoassay

Sample collection system and method for use thereof

Date/App# patent app List of recent Antibodies-related patents
10/09/14
20140303355
 Humanized anti-factor d antibodies and uses thereof patent thumbnailHumanized anti-factor d antibodies and uses thereof
The invention relates to humanized anti-human factor d monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease..
10/09/14
20140303354
 Anti-cd47 antibodies and methods of use thereof patent thumbnailAnti-cd47 antibodies and methods of use thereof
The invention relates to monoclonal and/or monovalent antibodies that bind cd47. The invention relates to monoclonal and/or monovalent antibodies that bind cd19.
10/09/14
20140302618
 Clozapine immunoassay patent thumbnailClozapine immunoassay
Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.. .
10/09/14
20140302617
 Sample collection system and method for use thereof patent thumbnailSample collection system and method for use thereof
A sample collection system capable of collecting, storing and dispensing a liquid sample is disclosed. The collection system includes a collector composed of a material which has the unique ability to express constituents of interest at levels which are much more concentrated than their levels in the fluid samples from which they are expressed, where the expressed highly concentrated sample can then be used with modern rapid screening/testing protocols, such as solid phase assays, to test for the constituents of interest.
10/09/14
20140302598
 Human antibodies specifically binding to the hepatitis b virus surface antigen patent thumbnailHuman antibodies specifically binding to the hepatitis b virus surface antigen
Provided are antibodies specifically binding to the hbv surface antigen (hbsag) which are effective for the prevention or treatment of hepatitis b.. .
10/09/14
20140302544
 A-fucosylation detection in antibodies patent thumbnailA-fucosylation detection in antibodies
This invention describes a new analytical method to determine the quantity and distribution of fucose per fc within an antibody preparation.. .
10/09/14
20140302534
 Anti-canine n-terminal pro-atrial natriuretic peptide antibody, and immunological measurement method and immunologically measuring kit using the same patent thumbnailAnti-canine n-terminal pro-atrial natriuretic peptide antibody, and immunological measurement method and immunologically measuring kit using the same
The anti-canine n-terminal pro-atrial natriuretic peptide antibodies (anti-canine nt-proanp antibodies) according to the present invention comprise anti-canine nt-proanp recognizing a partial portion or a whole portion of the amino acid sequence 31 to 67 of canine nt-proanp and anti-canine nt-proanp recognizing a partial portion or a whole portion of the amino acid sequence 68 to 98 thereof. The anti-canine nt-proanp antibodies are useful for immunologically measuring canine nt-proanp involved in heart diseases and infections of companion animals such as dogs, such as heart failure, mitral valve insufficiency and filariasis.
10/09/14
20140302524
 Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor patent thumbnailAntibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
The present disclosure provides lysyl oxidase-like-2 (loxl2) polypeptide binding agents, including, for example, antibodies that specifically bind a loxl2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided..
10/09/14
20140302498
 Rapid detection of the Rapid detection of the "high virulent" st-17 clone of group b streptococcus
The present invention also relates to kits and methods for the specific detection of group b streptococcus highly-virulent st-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.. .
10/09/14
20140302489
 Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof patent thumbnailIdentification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof
The invention relates to a polypeptide of a protective antigenic determinant (pad polypeptide) of porcine reproductive and respiratory syndrome virus (prrsv) and nucleic acids encoding a pad polypeptide. The pad polypeptide and nucleic acids encoding a pad polypeptide are useful in the development of antibodies directed to pad, vaccines effective in providing protection against prrsv infection, and diagnostic assays detecting the presence of pad antibodies generated by a pad-specific vaccine.
10/09/14
20140302172
Markers for susceptibility to an inhibitor of an src-family kinase
The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a kinase of the src family, such as dasatinib, bosutinib, saracatinib or ponatinib. The present invention also provides for a method for predicting the responsiveness of an individual to an inhibitor of a kinase of the src family, whereby the individual is suspected to suffer from cancer.
10/09/14
20140302144
Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts.
10/09/14
20140302085
Use of gk-1 peptide expressed on m13 filamentous phage as pharmaceutical ingredient to enhance the efficiency of the immune response induced by vaccine or pathogen antigens
The present invention is directed to the use of fgk-1 immunopotentiator, composed by the peptide named gk-1, characterized by the sequence g-y-y-y-p-s-d-p-n-t-f-y-a-p-p-y-s-a and linked to the pviii surface protein of m13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchoalveolar lavages.. .
10/09/14
20140302081
Hiv-1 gp120 mini v3 loop and uses thereof
The invention relates to an immunogenic hiv-1 gp120 mini v3 loop, which is a truncated version of the full-length gp120 v3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom.
10/09/14
20140302079
Novel influenza hemagglutinin protein-based vaccines
Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface.
10/09/14
20140302078
Haemophilus influenzae type b
Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
10/09/14
20140302070
Novel pd1 isoforms, and uses thereof for potentiating immune responses
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
10/09/14
20140302063
Influenza virus antibody compositions
The present invention relates to unique cdr3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine..
10/09/14
20140302062
Herpes simplex virus
The present invention relates, in general to herpes simplex virus (hsv) and, particular, to antibodies that are specific for glycoprotein d (gd) of hsv. The invention also relates to prophylactic and therapeutic uses of such antibodies..
10/09/14
20140302058
Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
10/09/14
20140302055
Antibodies directed to angiopoietin-like protein 4 and uses thereof
Antibodies directed to the antigen angptl4 and uses of such antibodies. In accordance with the teachings herein, there are provided fully human monoclonal antibodies directed to the antigen angptl4.
10/09/14
20140302054
Anti-gpr49 antibodies
Described herein are antibodies against gpr49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against gpr49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies..
10/09/14
20140302050
Targeting an amphiregulin-derived cell surface neo-epitope
Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies..
10/09/14
20140302049
Anti-gpr49 antibodies
Described herein are to antibodies against gpr49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against gpr49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies..
10/09/14
20140302047
Thrombin-binding antibody molecules and uses thereof
This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin..
10/09/14
20140302045
Igy composition for use in celiac disease
The present invention relates to an igy composition characterized in that said igy composition contains igy antibodies, fragments, and/or fab fragments thereof that specifically bind to a peptide with the amino acid sequence of seq id no: 1 and to the use of this igy composition in the therapy of celiac disease, rheumatism, and/or wheat allergy.. .
10/09/14
20140302041
Anti-axl antibodies and uses thereof
The present invention relates to anti-axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for axl comprising an heavy chain variable region comprising seq id no:2 in the h-cdr1 region, seq id no:3 in the h-cdr2 region and seq id no:4 in the h-cdr3 region; and a light chain variable region comprising seq id no: 6 in the l-cdr1 region, seq id no:7 in the l-cdr2 region and seq id no:8 in the l-cdr3 region.
10/09/14
20140302035
Anti-c-met tandem fc bispecific antibodies
Provided herein are tandem fcs and tandem fc antibodies (“tfcas”), e.g., tandem fc bispecific antibodies (“tfcbas”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a tfc, which tfc comprises a first fc region and a second fc region, wherein the first and the second fc regions are linked through a tfc linker to form a contiguous polypeptide and dimerize to form an fc dimer.
10/09/14
20140302034
Novel modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.. .
10/09/14
20140302033
Albumin binding antibodies and binding fragments thereof
A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in seq id no: 1 or seq id no:2 and/or comprising a light chain variable domain having the sequence given in seq id no:3 or seq id no:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in seq id no: 1 and seq id no:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in seq id no: 2 and seq id no:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides.
10/09/14
20140302032
Monoclonal antibodies for tumor treatment
A method of treating a tumor or enhancing survival of a subject having a tumor. The method includes (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has all complementarity determining regions of murine monoclonal antibody bat (mbat-1) and a framework region (fr) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent selected from the group consisting of: 5-fluorouracil, cytarabine, oxaliplatin, paclitaxel and combinations thereof.
10/09/14
20140302031
Targeting abcb5 for cancer therapy
The invention relates to methods for treating a subject by manipulating abcb5 on a cell as well as related products. The methods include methods of treating cancer using abcb5 binding molecules such as antibodies and fragments thereof..
10/09/14
20140302029
Anti-c-met/anti-egfr bispecific antibodies
There are provided an anti-c-met/anti-egfr bispecific antibody, a method for preventing and/or treating cancer using the same, and an anti-egfr scfv fragment.. .
10/09/14
20140302020
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma.
10/09/14
20140302016
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a cd154 (cd40l) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized fab fragment comprising a variable heavy chain sequence according to seq id no: 1 and comprising a variable light chain sequence according to seq id no: 2 specifically binds.
10/09/14
20140302015
Antibodies against human il33r and uses thereof
An antibody binding to il33r characterized in that the heavy chain variable domain comprises a cdr3 region of seq id no:1, a cdr2 region of seq id no:2 and a cdr1 region of seq id no:3 and in that the light chain variable domain comprises a cdr3 region of seq id no:4, a cdr2 region of seq id no:5 and a cdr1 region of seq id no:6 or a a chimeric, humanized or t cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.. .
10/09/14
20140301946
Antibody drug conjugates
The present invention relates to anti-fgfr2 and fgfr4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. .
10/09/14
20140301945
Human anti-sod1 antibodies
Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or sod1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for sod1 are also disclosed.
10/09/14
20140299468
High-performance analytical instrument and method
Apparatus and methods are provided for improving sensitivity, throughput, and efficiency of multi-analyte analytical testing. Specifically, an improved electrochemiluminescence (ecl) analytical apparatus is provided for analytical chemistry, diagnostics, and environmental applications.
10/02/14
20140298502
Desaturases and methods of using them for synthesis of polyunsaturated fatty acids
The amino acid and nucleic acid sequences of a Δ5-desaturase enzyme and a Δ8-desaturase enzyme are disclosed. The nucleic acid sequences can be used to design recombinant dna constructs and vectors.
10/02/14
20140296504
Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.
10/02/14
20140296492
Hla-restricted, peptide-specific antigen binding proteins
Antigen binding proteins with tcr-like paratopes, that is, with an antigen binding region specific for an hla-a2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv fragments.
10/02/14
20140296490
Highly galactosylated antibodies
In one aspect, the disclosure relates to antibodies that are highly galactosylated, methods of production of these antibodies and methods of use of these antibodies.. .
10/02/14
20140296488
Anti-notch nrr antibodies and methods using same
The invention provides anti-notch1 nrr antibodies, and compositions comprising and methods of using these antibodies.. .
10/02/14
20140296464
Chromatography medium
The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibres which form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same in chromatography, such as the isolation of recombinant proteins, monoclonal antibodies, viral vaccines and plasmid dna. The invention further provides for the use of the chromatographic medium in a simulated moving bed system..
10/02/14
20140296167
Glycosylation site-specific antibodies and anti-cancer compounds
A method of characterizing the protein o-glcnacylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific o-glcnacylated proteins expressed in cells and biological samples.
10/02/14
20140296132
Anti-bacterial polypeptides and pathogen specific synthetic antibodies
The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants.. .
10/02/14
20140296105
Antibody response phenotyping
Disclosed herein are methods, systems, mediums, and kits for use in phenotyping antibody responses via devices such as surface plasmon resonance devices. Such phentypes can include total target-specific antibody titers, quantitative isotype distribution of the target-specific antibodies, and/or epitope specificity of the target-specific antibodies.
10/02/14
20140296101
Secreted proteins and uses thereof
The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
10/02/14
20140295495
Methods of preventing and removing trisulfide bonds
The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures.
10/02/14
20140295494
High affinity, anti-human ige antibodies
The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin e (ige), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody.
10/02/14
20140295467
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
The present invention inter alia provides a method, and use thereof, of predicting severe cvd complications such as ami or cvd death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these cvd complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating cvd complications.
10/02/14
20140295466
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
The present invention inter alia provides a method, and use thereof, of predicting severe cvd complications such as ami or cvd death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these cvd complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating cvd complications.
10/02/14
20140295464
Detection of degradation products of feline nt-probnp
A method for determining the amount of nt-probnp in blood samples from felines. The method includes detecting degradation products of feline nt-probnp by various methods, including using antibodies, kits and devices..
10/02/14
20140295459
Markers for identifying tumor cells, methods and kit thereof
The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer.
10/02/14
20140294882
Compositions and methods for detecting, treating, and protecting against fusobacterium infection
The present invention relates to protecting against, treating, and detecting fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kda adhesin protein are provided to protect against, treat, and detect fusobacteria infections in a subject.
10/02/14
20140294867
Site-specific antibody-drug conjugation through glycoengineering
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or adcs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
10/02/14
20140294858
Subcutaneous administration of anti-hepatitis b antibodies
The present application relates to an immunoglobulin preparation comprising anti-hepatitis b antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis b virus. .
10/02/14
20140294857
Methods of obtaining a specific binding member that binds eotaxin
Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies vh and/or vl domain of the scfv fragment herein termed cat-212 and of the igg4 antibody herein termed cat 213.
10/02/14
20140294852
Monoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/02/14
20140294845
Anti-pleiotrophin antibodies and methods of use thereof
The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo.
10/02/14
20140294844
Prion protein antibodies for the treatment of alzheimer's disease
The invention relates to a ligand capable of binding prp at a site within amino acid residues 131 to 153 of prp, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding prp at a site within amino acid residues 131 to 153 of prp, for use in treatment or prevention of toxicity of aβ oligomers.
10/02/14
20140294841
T cell receptor-like antibodies specific for a wti peptide presented by hla-a2
The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
10/02/14
20140294839
Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
In sporadic alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of alzheimer's disease, which has remained elusive.
10/02/14
20140294838
Bispecific anti-cmet/anti-her2 antibodies
There are provided an anti-c-met/anti-her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.. .
10/02/14
20140294835
Novel heterodimeric proteins
The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first fc domain and a single chain fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second fc domains are different..
10/02/14
20140294834
Tandem fc bispecific antibodies
Provided herein are tandem fcs and tandem fc antibodies (“tfcas”), e.g., tandem fc bispecific antibodies (“tfcbas”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a tfc, which tfc comprises a first fc region and a second fc region, wherein the first and the second fc regions are linked through a tfc linker to form a contiguous polypeptide and dimerize to form an fc dimer.
10/02/14
20140294833
Novel heterodimeric proteins
The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first fc domain and a single chain fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second fc domains are different..
10/02/14
20140294832
Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (tfpi) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-tfpi monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided..
10/02/14
20140294831
Methods of treating a tauopathy
The present disclosure provides methods of treating a tauopathy, involving administering an anti-tau antibody. The present disclosure also provides anti-tau antibodies, and formulations comprising same, for use in the methods..
10/02/14
20140294829
Anti-ngf antibodies for the treatment of various disorders
The present invention relates generally to methods of using anti-ngf antibodies in the treatment of various ngf-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient..
10/02/14
20140294827
Fully human antibodies that bind to vegfr2
There is disclosed compositions and methods relating to anti-vegfr2 antibodies. More specifically, there is disclosed fully human antibodies that bind vegfr2, vegfr2-binding fragments and derivatives of such antibodies, and vegfr2-binding polypeptides comprising such fragments.
10/02/14
20140294825
Hybrid constant regions
The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least ch2 and ch3 regions of an igg or iga constant region and cμ3 and cμ4 regions of a cμ constant region.
10/02/14
20140294824
Antibodies that bind to ox40 and their uses
The present invention relates to antagonist antibodies or fragments thereof that bind to human ox40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human ox40 comprising a heavy chain cdr1 comprising the amino acid sequence of seq id no: 1, and/or a heavy chain cdr2 comprising the amino acid sequence of seq id no: 2, and/or a heavy chain cdr3 comprising the amino acid sequence of seq id no: 3; and/or comprising a light chain cdr1 comprising the amino acid sequence of seq id no: 4, and/or a light chain cdr2 comprising the amino acid sequence of seq id no: 5 and/or a light chain cdr3 comprising the amino acid sequence of seq id no: 6..
10/02/14
20140294819
Canine/feline cd20 binding epitope and compositions for binding thereto
The present invention provides acyclic polypeptide fragment of cd20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues sekns (seq id no:67); (ii) a first cysteine residue which is present at a region n-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which is present at a region c-terminal to the contiguous amino acid sequence, wherein the cyclic polypeptide is oxidised by the presence of a disulphide bond formed between the first and second cysteine residues. Also described is the use of the cyclic peptide fragment to generate antibodies which bind specifically to cd20.
10/02/14
20140294815
Caninised tumour necrosis factor antibodies and methods of using the same
Caninised and chimeric antibodies and antigen binding fragments thereof which bind specifically to canine tumour necrosis factor and inhibit the ability of canine tnf to bind to the tnfr1 receptor are provided. The invention further extends to nucleic acids encoding same and to methods of treating chronic inflammatory disease such as arthritis in a canine using said antibodies and/or nucleic acids..
10/02/14
20140294812
Fc variants that improve fcrn binding and/or increase antibody half-life
The present invention discloses the generation of novel variants of fc domains, including those found in antibodies, fc fusions, and immuno-adhesions, which have an increased binding to the fcrn receptor and/or increased serum half-life.. .
10/02/14
20140294809
Anti-alpha(v)beta(6) antibodies and uses thereof
The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin.
10/02/14
20140294807
Combination therapy with type i and type ii anti-cd20 antibodies
The present invention is directed to a combination therapy involving a type i anti-cd20 antibody and a type ii anti-cd20 antibody for the treatment of a patient suffering from cancer, particularly a cd20-expressing cancer. An aspect of the invention is a composition comprising a type i anti-cd20 antibody and a type ii anti-cd20 antibody.
10/02/14
20140294765
Lsr antibodies, and uses thereof for treatment of cancer
This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for lsr molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.. .
10/02/14
20140294758
Light chain immunoglobulin fusion proteins and methods of use thereof
Provided are recombinant antibodies comprising one or more peptides fused to the c-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the c-terminus of the light chain constant region are described and shown to be surprisingly active..
10/02/14
20140294731
Phosphospecific antibodies recognising tau
The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including alzheimer's disease (ad).. .
10/02/14
20140294722
Anti-pancreatic cancer antibodies
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers.


Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.6368

4149

1 - 1 - 89